More Than Fifteen Percent of All Contact Lens Users Are Forced to Give up Lens Wear Every Year Because of Inflammation and Discomfort, Says a Nationally Recognized Eye Doctor; But New Treatments Can Help Them Comfortably Wear Lenses Again

PHOENIX, AZ / ACCESSWIRE / June 28, 2016 / Dr. Arthur Epstein, Director of Ocular Surface Disease and Clinical Research at Phoenix Eye Care, one of the nation’s leading eye care practices, believes that increasing contact lens intolerance has led to a rise in the number of dramatic new treatments that can restore people’s ability to comfortably wear contact lenses. “At least fifteen percent of all contact lens users discontinue wearing contacts every year because of inflammation and pain,” said Epstein. “Now eye doctors nationwide are using innovative new treatments that offer hope to contact lens users.”

“Years of experience has shown that contact lenses can be amazing devices that can improve people’s lives in the most incredible ways,” said Dr. Epstein. “Unfortunately, far too many people have been forced to give up wearing lenses because of dryness, inflammation and discomfort. In fact, the most common reason for contact lens dropout is dry eye, caused by an unstable tear film that can’t support comfortable contact lens wear. Additionally, tiny organisms–bacteria and even microscopic parasitic mites–that live on the eyelids can worsen the problem. The microbes produce inflammatory toxins that irritate sensitive eye tissue while enzymes break down the protective outer oil layer of the tear film. The mites contribute to inflammation. Both can cause a chronic inflammatory condition of the lids called blepharitis.”

Overall, fifteen
percent of people suffer from contact lens intolerance; however, that percentage soars up to 30 percent for those over 50 years old. “This is a serious and growing problem,” said Dr. Epstein.

According to Dr. Epstein, three new developments in eye care now enable eye doctors to successfully treat most of these people:

• A new device called LipiFlow applies a precise amount of heat and controlled pressure to the inner eyelid, unblocking clogged meibomian glands releasing a crucial oil, that stabilizes the tears, improves dry eye and dramatically increases contact lens comfort.
• A handheld device called BlephEx uses a high-speed disposable sponge to ‘deep clean’ the lid margins. It successfully knocks back the blepharitis and the crusty buildup of debris that often occurs.
• An innovative lid and lash hygiene product, Avenova® from NovaBay
  Pharmaceuticals (NYSE MKT: NBY), uses a pure 0.01% concentration of hypochlorous acid (HOCl) in saline to remove the bacteria and mites associated with chronic eyelid disease, like blepharitis and MGD
  dry eye. HOCl is completely safe. It is produced naturally by white blood cells as a first defense against microbial invaders, and also inactivates bacterial enzymes, helping to stabilize the tear film and improve comfort.

“Avenova has been a true breakthrough for dry eye and contact lens patients. Applying it to the eyelids twice a day as part of a daily eyelid hygiene regimen can help reduce contact lens intolerance in many patients,” said Dr. Epstein. “So if you have this problem, speak to your eye doctor. He or she can now really help you.”

Contact:

Dr. Arthur Epstein
Phoenix Eye Care
Office: 602-549-2020
Cell: 516-885-2020
Email:
artepstein@artepstein.com;
artepstein@gmail.com

SOURCE: CEOCFO Magazine

ReleaseID: 441474

NEW YORK, NY / ACCESSWIRE / June 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed on behalf of those who purchased shares of Deutsche
Bank AG (“Deutsche Bank” or the “Company”) (NYSE: DB) from April 15, 2013 through April 29,
2016, both dates inclusive (the “Class Period”).

The Complaint alleges that throughout the Class Period, Defendants issued false and misleading statements to investors
and/or failed to disclose that: (1) Deutsche Bank has serious and systemic failings in its controls against financing terrorism, money laundering, aiding against international sanctions, and committing financial crimes; (2) Deutsche Bank’s internal control over financial reporting and its disclosure controls and procedures were not effective; and (3) consequentially, the Defendants’ statements about Deutsche Bank’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!db/tqcum. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Deutsche Bank AG you have until July
11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441323

NEW YORK, NY / ACCESSWIRE / June 28, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors
of class action against of Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ: NVCN). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Neovasc securities during the period between January 26, 2015, and May 19, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Neovasc is a specialty medical company that develops cardiovascular products. Neovasc’s primary product is the Tiara, a transcatheter mitral valve device used to treat mitral valve disease. This device can be implanted through minimally invasive surgery to patients with mitral regurgitation resulting from mitral heart valve disease.

The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about Neovasc’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) Neovasc’s Tiara device was advanced through dishonest business practices, including the embezzlement of trade secrets from another company; (2) that there was a related and legitimate lawsuit against Neovasc regarding
the misappropriation of trades secrets; and (3) consequentially, Defendants’ statements about Neovasc’s business, operations, and prospects were materially false and misleading at relevant times. Following this information entering the market, investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm’s website: http://www.bgandg.com/#!nvcn/m3197. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Neovasc you have until August 5, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441331

NEW YORK, NY / ACCESSWIRE / June 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed against certain officers of SunEdison Inc. (“SunEdison” or the “Company”) in the United States District Court for the Eastern District of Missouri on behalf of those who purchased shares of Vivint Solar, Inc. (“Vivint Solar” or the “Company”) (NYSE: VSLR) during the period between the July 20, 2015 and March 7, 2016, inclusive (the “Class Period”).

Vivint Solar, Inc. is an American solar energy company. In July 2015 SunEdison and Vivint announced a merger that SunEdison would acquire Vivint. Following this release, Vivint’s stock increased $4.87, or roughly 44.8%, to close at $15.75 per share. On February 24, 2016, at the Vivint’s shareholders meeting, investors voted in favor of the SunEdison merger.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or failed to disclose that: (1) SunEdison would not be able to attain financing for the acquisition of Vivint; (2) SunEdison’s earnings were less than Defendants had stated; (3) SunEdison would be unable to complete the acquisition of Vivint; and (4) consequentially, Defendants’ statements regarding the SunEdison and Vivint merger were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On February 29, 2016, post-market, SunEdison filed a Notification of Late Filing on Form 12b-25 with the SEC, unveiling that it would be late to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The Notification of Late Filing included information that in late 2015, former SunEdison executives had made accusations of the truthfulness in SunEdison’s financial statements. Following this news, Vivint stock dropped $1.37 per share, or more than 17%, to close at $6.52 per share on March 1, 2016.

On March 2, 2016, The Wall Street Journal printed an article, “SunEdison’s Takeover of Vivint Solar in Jeopardy as Banks Balk” explaining how the Vivint-SunEdison merger was at risk.

Following this news, Vivint stock dropped $1.63 per share, or 25%, to close at $4.89 per share on March 2, 2016.

On March 8, 2016, Vivint announced the Merger Agreement was cancelled. On that same day Vivint also filed a lawsuit against SunEdison in Delaware Chancery Court claiming it breached the contract. Following this news, Vivint stock dropped $1.04 per share, or roughly 20%, to close at $5.21 per share on March 7, 2016.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, please visit the firm’s site: http://www.bgandg.com/#!vslr/wwxww. You can also contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Vivint Solar you have until July 5, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441713

NEW YORK, NY / ACCESSWIRE / June 28, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court, Southern District of New York on behalf of those who purchased shares of Endo International plc (“Endo” or the “Company”) (NASDAQ: ENDP) between March 2, 2015 and May 6, 2016 inclusive (the “Class Period”).

According to the Complaint, throughout the class period, Endo stated in filings with the U.S. Securities and Exchange Commission (“SEC”) that its net sales for its U.S. Branded Pharmaceuticals segment improved, due to increased proceeds from Frova, Endo’s migraine therapy. Endo’s filings with the SEC included signed certifications that the financial information was correct and revealed any material changes to Endo’s internal control over financial reporting. In Endo’s 2015 Earnings Release, it estimated total revenues between $4.32 billion and $4.52 billion for the year ended December 31, 2016. On March 17, 2016, Endo announced at a conference that its revenue guidance did not meet expectations for the first quarter of 2016, but restated the revenue guidance from the 2015 Earnings Release.

The complaint alleges that Endo officials failed to disclose that its contracts with pharmacy benefit managers (“PBMs”) for Frova included questionable inducements planned increase sales that Endo’s revenues relied on.

On May 5, 2016, Endo announced poor financial results, severely cutting its 2016 guidance, and revealed that the President of the company’s U.S. Branded Pharmaceuticals segment was resigning. Endo also announced that in March of 2016 its subsidiary, Endo Pharmaceuticals Inc., had received a request for documents from the U.S. Attorney’s Office for the Southern District of New York “regarding contracts with Pharmacy Benefit Managers regarding [the migraine treatment] Frova.” Following these news reports, Endo’s stock dropped $11.32 per share, or 42.57%, to close at $15.27 per share on May 9, 2016.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!endo/v6ep3. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Endo you have until July 25, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441211

How GPS Technology and Data Are Helping the Golf Business Monetize More Effectively

SURREY, BC / ACCESSWIRE / June 28, 2016 / DSG GLOBAL INC. (OTCQB: DSGT) is a proven industry leader, whose TAG Systems solution is used by over 300 major golf courses around the world to track their fleets of golf carts and turf equipment. DSG with its sophisticated data capturing technology is quickly becoming a leader of data capture in the golf industry.

“There’s Google, Apple and now DSG,” said Adrian Fulle, Chief Marketing Technologist at DSG. “Our digital assets are already deployed on hundreds of golf courses around the world and we are in a unique position to capture data on fleets of golf carts and golf courses.”

(To learn more about DSG TAG Systems click here) (For Company Profile click here)

The company’s executive team has over 50 years of combined experience in GPS technology and the company spent millions of dollars developing their solutions. The simple, but effective TAG System is a solution for fleet managers and operators by providing smart routing, 24/7 monitoring and real-time alerts to increase productivity and safety.

Through their interactive TOUCH solution on golf carts and other fleet vehicles, DSG is able to gather intelligent data about key consumer habits.

“Golf is one of the best consumer segments for data gathering,” explained Fulle. “Golfers are among the most affluent and have high disposable income. And when they’re playing a round of golf, they’re a captivated audience for 4 hours or more and they’re most likely to interact with our digital assets. It doesn’t get much better than that for advertisers.”

The data collected through this technology has become a valuable asset for the company and its clients. The company’s R3 advertising revenue program, due to launch in July, will utilize this data to the advantage of courses and advertisers.

“Knowing your fleet history and how your fleet operates from the micro to the macro is extremely important for making informed decisions on future operations, but knowing your consumer, the golfer, is just as valuable. It allows the golf course operators to create better and better experiences for the golfing consumer and for advertisers to display more and more relevant advertising. It’s win-win for everyone,” added Fulle.

Visit DSG Global at dsgtag.com or FACEBOOK or TWITTER.

Safe Harbor for Forward-Looking Statements

This information contains forward-looking statements. Forward looking statements in this press release include statements relating to the Company’s corporate finance and other strategic initiatives, and the Company’s expansion into markets outside of the golf industry. Forward-looking statements are inherently subject to risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, the following: the timing and nature of any capital raising transactions; our ability to offer products and services for use by customers in new markets outside of the golf industry; the risk of competition; our ability to find, recruit and retain personnel with knowledge and experience in selling products and services in these new markets; our ability to manage growth; and general market, economic and business conditions. Additional factors that could cause actual results to differ materially from those anticipated by our forward-looking statements are under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” filed with the Securities and Exchange Commission. The Company disclaims any obligation or undertaking to update forward-looking statements.

For information please contact Investor Relations:

DSG Global Inc.
(877) 589-8806

SOURCE: DSG Global Inc.

ReleaseID: 441739

LAS VEGAS, NV / ACCESSWIRE / June 28, 2016 / Golden Matrix Group Inc. (OTCPK: GMGI) a provider of Social Gaming Technology launches Lucky Panda 888 iPhone App. https://itunes.apple.com/us/app/lucky-panda-888-casino/id1094179903?mt=8.

The company recently launched its first iPhone App with multiple Social casino games.

The new offering will add value and revenues to its existing game portfolio and in particular to the newly established distribution agreement with L.H. Information and Technology (LHIT) in Hong Kong. LHIT is one of Asia’s leading Social Gaming Operators. LHIT has an extensive active customer base and will offer the exciting new Lucky Panda Apps to its customer base.

Brian Goodman, CEO stated that, “Having a strong mobile presence is critical, the exciting Social Casino Apps will further enhance the company’s revenues and its overall positioning in the Social Gaming arena. Global revenue from mobile in-application sales has surpassed 14 billion US dollars in 2015. While mobile Apps become more popular and mobile Internet more widely available, revenues generated from applications are reaching unprecedented records. In 2016, it is estimated that worldwide consumers will spend some 50 billion U.S. dollars on mobile Apps via App stores, but this number is expected to double by 2020.”

“Social casino games have become a $2.7 billion worldwide industry in a short few years thanks to rapid growth on Facebook and mobile. Golden Matrix Group has the skills and technology that are necessary to compete in the growing global market and in particular the Asian markets where culturally relevant content is a necessity. As the company introduces new gaming applications they will include popular casino games, poker, bingo, Slots and table games to be offered in a Social Environment.”

About Golden Matrix Group

Golden Galaxy Group owns Social Gaming IP and builds configurable and scalable white labeled social gaming platforms for its international customers and delivers innovation that players want. The Social Gaming IP includes tools for acquisition, retention and monetization of users. The Company’s platform is unparalleled in both desktop and mobile applications. Moreover user management is optimized though its ability to accommodate both free and cost to play state of the art games.

Brett Goodman – brett@goldenmatrix.com

SOURCE: Golden Matrix Group

ReleaseID: 441738